STOCK TITAN
  1. Home
  2. Sec-filings
  3. IMA
  4. [Form 4] ImageneBio, Inc. Insider Trading Activity

Director Joseph Slattery receives 15,600 ImageneBio (IMA) stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ImageneBio, Inc. director Joseph P. Slattery reported receiving a stock option grant as equity compensation. The award covers 15,600 shares of common stock at an exercise price of $5.45 per share, expiring on June 16, 2036.

According to the terms, the option vests in full on the earlier of the first anniversary of the grant date, the company’s next annual meeting, or a change of control as defined in ImageneBio’s 2025 Equity Incentive Plan. After this grant, Slattery holds options for 15,600 shares directly.

Positive

  • None.

Negative

  • None.
Insider SLATTERY JOSEPH P
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 15,600 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 15,600 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 15,600 shares Underlying common stock in new stock option award
Option exercise price $5.45 per share Strike price for newly granted options
Options held after grant 15,600 options Total derivative securities following transaction
Option expiration date June 16, 2036 Expiration of stock option grant
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
Equity Incentive Plan financial
"defined in the Issuer's 2025 Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
change of control financial
"the date of the Issuer's next annual meeting or a change of control"
A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SLATTERY JOSEPH P
(Last)(First)(Middle)
C/O IMAGENEBIO, INC.
2526 HIGH BLUFF DRIVE
(Street)
SAN DIEGO CALIFORNIA 92130
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
ImageneBio, Inc. [ IMA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$5.4506/16/2026A15,600 (1)06/16/2036Common Stock15,600$015,600D
Explanation of Responses:
1. The shares vest in full upon the earlier to occur of the first anniversary of the date of grant, the date of the Issuer's next annual meeting or a change of control as defined in the Issuer's 2025 Equity Incentive Plan.
/s/ Kristin Yarema, Attorney-in-Fact06/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did ImageneBio (IMA) director Joseph P. Slattery report in this Form 4?

Joseph P. Slattery reported receiving a grant of stock options for 15,600 shares of ImageneBio common stock. These options were awarded as compensation, with a fixed exercise price and a defined future expiration date.

How many ImageneBio (IMA) shares are covered by the new stock option grant?

The stock option grant covers 15,600 underlying shares of ImageneBio common stock. This entire amount vests as a single tranche once specified conditions are met, giving Slattery the right to purchase these shares at a set exercise price.

What is the exercise price and expiration date of Joseph Slattery’s ImageneBio options?

The options have an exercise price of $5.45 per share and expire on June 16, 2036. This means Slattery can choose to buy shares at $5.45 any time after vesting and before the 2036 expiration date.

When do Joseph Slattery’s ImageneBio (IMA) stock options vest?

The options vest in full on the earliest of three events: the first anniversary of the grant date, ImageneBio’s next annual meeting, or a qualifying change of control under the company’s 2025 Equity Incentive Plan.

Is Joseph P. Slattery’s Form 4 transaction a market purchase or sale of ImageneBio shares?

The Form 4 reports a grant of stock options, not a market purchase or sale. It reflects an equity compensation award, giving Slattery future rights to buy shares rather than an immediate open-market transaction.